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Abstract
It has been 40 years since Folkman’s seminal paper [Cancer Res 1974. 34:2109-13], proposing the presence of a 
tumour associated angiogenic factor, which could be targeted as an anticancer therapy. There are currently a handful 
of drugs in trial or use that have been marketed as targeting angiogenesis. Unfortunately, the most widely used 
of these, bevacizumab (Avastin™, Roche), has met with limited success clinically. For this reason and based on a 
calculation of cost benefit, bevacizumab is now only publically subsidised for use in a limited range of solid tumours. 
That the contribution of vasculature to malignancy remains poorly understood is increasingly clear. At the same time, 
the traditional view that vascularisation is a passive participant in the process of malignancy, and that endothelium 
merely provides a conduit by which tumour cells spread, is being replaced with an understanding that vasculature is 
a key player in the process of metastasis. Furthermore, the identification of non-traditional sources of vasculature has 
complicated our understanding of the tumour endothelium as a unique population that can be simply targeted as an 
anticancer therapy. The following review seeks to provide an up-to-date view of vascular contribution to metastasis 
and implications for new vasculature-targeted anticancer treatments.
At face value, the vascular contribution to metastasis is not 
self-evident. Many lesions that a patient may present with 
are vascular, despite being poorly malignant or benign. 
Consequently, the relationship between vascularity, 
tumour growth and malignancy remains controversial. 
In many instances, tumours can present with metastatic 
lesions, while the primary lesion remains relatively small, 
or undetected.1 Conversely, relatively large and highly 
vascular breast lumps can also remain undetected and 
benign for many years. Yet despite these observations, 
vascularisation and spread are closely linked with clinical 
course in many solid tumours, including breast cancer.
While benign tumours can either be vascular or relatively 
avascular, almost all malignant tumours are vascular. 
Furthermore, while distal lymph node metastasis remains 
the main pathological indicator of grade, it is increasingly 
clear that spread via the lymphatics is a later event 
in metastasis.2 This is supported by the detection of 
disseminated tumour cells in the peripheral blood and 
bone marrow of patients with early stage breast cancer.2 
Haematologic dissemination of tumour cells may therefore 
be considered the initial route for early spread of the tumour, 
although evidence for this to date remains circumstantial. 
Regardless, because of its important role in cancer spread, 
the role that vasculature plays in establishment and growth 
of metastasis at a secondary site has occupied a lot of 
research effort. It has been known for several years that 
drugs targeting vascular endothelial growth factor (VEGF) 
can enhance the anti-tumour effects of cytotoxic drugs. 
While the mechanism for this is uncertain, it is proposed 
that the effectiveness of combination therapies slows 
angiogenesis, leading to a normalisation of the vascular 
tree, and enhanced drug delivery.3 However, many of 
these therapies are associated with the onset of adaptive 
resistance (a loss of response to therapy),4 as well as a 
tumour environment that is selective for the development 
of highly aggressive tumour cells.
Understanding the role that vasculature plays in malignancy 
is key to the effective use of current therapies, and in the 
development of future effective therapies. To date, despite 
a sustained research effort over many years, only a handful 
of anti-angiogenic drugs are in clinical use.
Anti-angiogenic therapy
The Food and Drug Administration (FDA) in the US has 
approved several drugs that have antiangiogenic activity, 
including bevacizumab (Avastin®). Bevacizumab is the 
most widely used antiangiogenic therapy. It is designed 
to stop VEGF signalling and thus vascular growth. The 
FDA has approved bevacizumab to be used alone for, 
glioblastoma and in combination with other drugs for 
the treatment of: (i) metastatic colorectal cancer; (ii) non-
small cell lung cancers; and (iii) renal cell cancer. Alone, 
bevacizumab is ineffective for the treatment of certain 
cancers, or is effective for a very short period of time as 
a result of adaptive resistance.5 When combined with 
traditional chemotherapy (such as FOLFOX or FOLFIRI), 
bevacizumab provides colorectal cancer patients an 
average increase in survival of ﬁ ve months. Patients with 
advanced non-small-cell lung cancer have an average 
increase in survival of about two months.6 These increases 
in survival in patients with highly advanced disease are 
signiﬁ cant, and it should be emphasised that they may 
translate into longer individual survival expectations when 
used in the actual target group.
The effectiveness of bevacizumab treatment in breast 
cancer has been more controversial. Although phase III 
trials of bevacizumab plus chemotherapy demonstrate 
modest effectiveness in metastatic breast cancer, 
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these trials used progression free survival as a measure 
of efﬁ cacy.7 However, breast cancer populations are 
heterogeneous, and contain rare cell populations that are 
undetectable and capable of proliferating aggressively 
regardless of tumour size.5,8 In contrast, clinical trials using 
overall survival fail to show clinical advantage to the use 
of bevacizumab. Furthermore, a signiﬁ cant proportion 
(2.5%) of patients on bevacizumab therapy will experience 
a fatal adverse event, resulting from haemorrhage. These 
include neutropenia with lethal infection, gastrointestinal 
tract perforation, pulmonary embolism and cardiovascular 
accident.9 There are also a range of side-effects associated 
with bevacizumab therapy, including hypertension, 
cardiac toxicity, neutropenia, thromboembolisms, stroke, 
enhanced chemotherapy toxicity and impaired wound 
healing resulting in severe bleeding.9,10 Finally, bevacizumab 
doubles the cost of chemotherapy to $100,000 USD per 
patient per year. For these reasons, as of December 2010, 
after only two years of use, the FDA withdrew bevacizumab 
treatment for metastatic breast cancer. The Therapeutic 
Goods Administration in Australia, and the National Health 
Service in the United Kingdom, have followed suit and 
do not provide government funding for bevacizumab 
treatment of malignant breast cancer.
Given the lack of effectiveness of bevacizumab in 
advanced breast cancer, but the clear advantage in 
other types of cancer, there remains a need for improved 
anti-angiogenic therapies, as well as the need to obtain 
a greater understanding of the underlying mechanisms 
supporting breast cancer angiogenesis, resistance and 
progression.
Mechanisms of neovascularisation
The classical model for tumour neovascularisation 
proposes that as a solid tumour grows, it ﬁ rst starts by 
co-opting pre-existing vessels, without vasculogenesis (de 
novo generation of vessels), and by recruiting pre-existing 
endothelial cells from surrounding tissues (angiogenesis) 
(ﬁ gure 1). The transition from an avascular adenoma to 
a fully vascular, metastasising lesion, is referred to as 
the angiogenic switch, and its onset is associated with 
rapid tumour growth.11 Fifteen years ago, Asahara put 
forward a further mechanism by which tumours recruited 
vasculature.12 He proposed that a certain proportion 
of tumour vasculature was derived de novo from bone 
marrow adult stem cells. Since then, bone marrow derived 
endothelial progenitor cells (EPCs), with vasculogenic 
potential and capable of luminal incorporation into the 
vascular tree, have been identiﬁ ed as an alternate source 
of tumour vasculature.13-16
More recently, several post-classical mechanisms of 
neovascularisation have come to light, including tumour 
cells themselves,17 myeloid cells and tissue resident 
mesenchymal stem cells (MSCs),18 All of these populations 
have been found to acquire vascular markers and mimic 
endothelial cell biology, and therefore must be considered 
in the development of anti-angiogenic therapies. However, 
the role of vasculogenesis and vascular mimicry in the 
adult remains controversial because of the numbers of 
cells implicated in tumour pathology, and because of 
limitations in the tools available to study them.19
Vessel co-option
In vessel co-option, neither vasculogenesis nor 
angiogenesis play a role. Instead, the growing tumour 
simply incorporates existing vasculature from the 
host tissue bed.20 Studies suggest that vessel co-
option occurs in the initial stages of tumour growth.21 
Notably, tumour regrowth following anti-angiogenic 
therapy commonly involves vessel co-option, in 
addition to both angiogenesis and vasculogenesis.22
Angiogenesis 
Angiogenesis refers to the formation of new blood vessels 
from pre-existing vessels, and occurs concurrently with 
vasculogenesis in a rapidly vascularising tumour.23 During 
angiogenesis, hypoxia drives vessel sprouting via VEGF 
mediated proliferation of endothelial cells, and basement 
membrane remodelling.24 Sprouts invade surrounding 
tissues as a proliferating solid stalk, which is guided by a ‘tip 
cell’, possessing numerous ﬁ lopodia that sense gradients 
of angiogenic molecules.25 Formation of a functional lumen 
and integration into existing vascular structures follow. 
As a consequence, sprouting angiogenesis is slow to 
develop an organised structure and is dependent upon 
cell proliferation, as well as the activation of molecular 
pathways that support tissue invasion. Vessels formed in 
this way tend to be disorganised, leaky and disconnected 
from the existing vascular tree.23
Distinct from sprouting angiogenesis, intussusceptive 
angiogenesis is characterised by the formation of 
Day 7
Day 13 Day 16
Day 10
Angiogenesis Vasculogenesis Mimicry Co-option
Sprouting EPCs Tumour Cells MSCs
Myeloid cells
Intussesception
Figure 1: Upper, schematic representation of the process 
underlying tumour neovascularisation, showing sprouting/
intussesception angiogenesis, co-option, vasculogenesis and 
tumour mimicry. Lower, murine breast tumours at day 7, day 
10, day 13 and day 16, showing progressive neovascularisation 
with time.
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transvascular tissue pillars across the vessel lumen.26 
Vessel walls join together, leading to the formation of 
a transverse endothelial bilayer, or pillar. The pillar then 
undergoes perforation, and dilatation. This is followed by 
branching and further development, including invasion of 
ﬁ broblasts and pericytes, as well as the laying down of 
interstitial matrix.27 As a consequence, intussusceptive 
angiogenesis leads to rapid neovascular branching 
(occurring in hours or even minutes), and does not require 
cell division. Once started, intussusception can dramatically 
increase vascular surface area, and unlike sprouting, 
allows for continuous blood during vessel formation. 
Intussusceptive angiogenesis has been demonstrated in 
a range of cancers, and is linked to regression following 
anti-cancer therapy.28,29 While no single molecule has been 
implicated as a driver of intussusception, shear stress has 
been shown to play a role.30 
Vasculogenesis 
In embryology, vasculogenesis refers to the de novo 
formation of blood vessels from the differentiation of 
mesodermal precursor cells, referred to as endothelial 
precursor cells (EPCs).31 There are two main theories for 
the origins of embryonic EPCs: (i) the idea that there exists 
a bipotential haemangioblast that comes directly from 
mesoderm and forms both the early vasculature as well 
as the haematopoietic system, and (ii) the proposition that 
there exists haemogenic endothelium (haemangioblast), 
an endothelial cell intermediate with haematopoietic 
potential which is not derived directly from mesoderm.32-34 
While studies suggest that the haemangioblast is the 
source of both haematopoetic cells and the majority of 
endothelium in embryos, the haemangioblast in adults 
remains undeﬁ ned.
EPCs can collect both in normal and cancerous tissues, 
and contribute to de novo blood vessel growth.13-16,35 
Since they were proposed, observations have shown that 
circulating EPCs contribute to tumour angiogenesis.14,36 
However, because of their small number and because 
circulating vasculature shed from the tumours expresses 
many markers that are similar to EPCs, consensus as 
to their importance in human cancer biology has been 
difﬁ cult to arrive at.37 In 2005, Peters et al demonstrated 
conclusively that EPCs were present in human cancer.13 
This was supported by studies in mice,14-16 which showed 
that EPCs could be tracked from the bone marrow to 
luminal incorporation into tumour vascular and that they 
were present at the tumour periphery in the early stages of 
the angiogenic switch. In 2008, Gao et al 15 demonstrated 
that metastases also underwent an EPC dependent 
angiogenic switch. At the time, it was not self-evident that 
a metastasis, which had already undergone an angiogenic 
switch prior to spread, would have to undergo further 
changes to recruit vasculature to a secondary site. The 
fact that EPCs are not only participants in metastasis, but 
signiﬁ cant players in driving malignant spread, has made 
them important targets of anticancer therapy.
Vascular mimicry 
In addition to EPCs, some aggressive cancers show 
a remarkable functional plasticity, exhibiting the 
phenomenon of vasculogenic, or vascular mimicry.17 
During vascular mimicry, cancer cells and/or cells of a non-
endothelial lineage begin to express genes associated 
with angiogenesis and vasculogenesis, assuming some 
phenotypic traits of endothelial cells, including luminal 
incorporation. Vascular mimicry is driven by tumour 
hypoxia, and tumours displaying vascular mimicry exhibit 
a matrix-rich, vasculogenic-like network, lined with 
transendothelial tumour cells that have assumed the 
function of endothelial cells.38 The earliest description of 
vascular mimicry was reported in melanoma by Maniotis,39 
who described vascular-like networks of tubular and non-
tubular structures, which were rich in collagen, possessing 
a basement membrane lined with tumour cells co-
expressing endothelial markers, and containing plasma 
and red blood cells. Further work has demonstrated 
similar structures in a range of aggressive tumour types, 
including carcinomas, sarcomas, glioblastomas and 
astrocytomas.40-42 Tumour cells displaying vascular 
mimicry show phenotypic plasticity similar to embryonic 
stem cells, expressing key stem cell markers,43 as well as 
expression of endothelial markers such as VE-cadherin, 
erythropoietin-producing hepatocellular carcinoma-A2, 
and extracellular matrix proteins (laminin V, ﬁ bronectin and 
collagen IV and VI), and down-regulation of genes that are 
cancer/epithelial cell speciﬁ c.44
Functionally, the leaky vessels created via vascular 
mimicry provide an alternate perfusion route. Furthermore, 
channels of vascular mimicry may also connect to vessels, 
increasing the overall perfusion of the tumour, as well as 
providing a pathway for metastasis. Clinically vascular 
mimicry, although rare, is associated with poor prognosis, 
suggesting that it confers an advantage in tumour 
progression. Furthermore, as tumour cells displaying 
vascular mimicry lack the regulatory constraints on growth 
and differentiation displayed by normal endothelial cells, 
and are genetically unstable, they would be subject to the 
same propensity that cancer cells have to develop drug 
resistance.
In addition to tumour cells, there is a growing recognition 
that host derived cells with nonvascular lineages may 
also begin to express markers normally associated 
with endothelial cells. By far the best-studied bone 
marrow-derived tumour inﬁ ltrating cells contributing to 
angiogenesis, which may be candidates for myeloid 
vascular mimicry, are tumour-associated macrophages 
(TAMs).45 As with EPCs, TAMs are recruited in response to 
tumour derived chemokines and growth factors.46 TAMs 
produce pro-angiogenic molecules VEGF, interleukin-8, 
tumour necrosis factor-α and matrix metalloproteinase-9 
(MMP-9).47 Correspondingly, high numbers of TAMs often 
correlate with tumour vascularisation.18,48 In addition, 
there is increasing evidence that TAMs start to express 
endothelial factors such as CD31 and they may contribute 
to tumour vasculature directly, although there is little 
evidence of luminal incorporation as endothelium and their 
role may be solely perivascular. 
MSCs are found in many tissues, including bone marrow, 
and represent another heterogeneous stromal cell 
lineage that has been implicated in tumour angiogenesis 
and growth. Tissue resident MSCs play a role in the 
maintenance and regeneration of connective tissues 
through engraftment.49,50 During cancer, signiﬁ cant 
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numbers of MSCs are recruited to the site of the primary 
tumour, where they play a role in invasion, metastasis and 
immunological evasion.51,52 Non-bone marrow derived 
MSCs have recently been proposed as a source of 
vasculature in certain tumours.53 
Dormancy and the endothelium
Studies in breast cancer metastasis have shown that 
dormant disseminated tumour cells reside within the 
lumen of microvasculature at common metastatic 
destinations such as the lung, bone marrow and brain.54 
Three-dimensional modelling of microvasculature in vitro 
has conﬁ rmed that the perivascular location of tumour 
cells is responsible for maintaining their quiescent state. It 
has also been shown that the protein thrombospondin-1 
is secreted by endothelial cells, and can act to suppress 
tumour-cell growth at a secondary site.54 Remarkably, 
this growth-suppressive microenvironment is found 
only around stable vasculature. Activated or sprouting 
tips of newly forming vessels actually have a growth-
accelerating effect on tumour cells, through expression of 
pro-metastatic proteins, including periostin, tenascin-C, 
ﬁ bronectin and tumour growth factor-β1. Recent work by 
Wells et al. (University of Pittsburgh Medical Centre, US) 
has shown that transformed endothelial cells from the liver 
also confer a proliferative advantage to breast cancer cells, 
via the epidermal growth factor pathway.55 While the role 
of endothelial cells in maintaining dormancy has yet to be 
shown in vivo, emerging lines of evidence such as these 
are compelling and provide the ﬁ rst tantalising glimpse of 
the importance of the vascular tree in regulating growth of 
secondary metastases.
Conclusion
Tumour neovascularisation is complex, involving both 
interlinked and distinct processes. Recruitment of 
pre-existing vasculature is characterised by complex 
architectural changes to the existing vascular tree. 
Furthermore, our lab and others,14-16 have shown that 
EPCs and other bone marrow derived cells are signiﬁ cant 
drivers of angiogenesis and spread, and may be the main 
factor underlying development of adaptive resistance. It is 
also evident that other vasculogenic populations such as 
tumour cells themselves and cells of non-bone marrow/
non-endothelial origin, are also important drivers of clinical 
course in cancer. The understanding that endothelial cells 
at the site of secondary metastasis can regulate growth 
and further spread directly, is a new revelation in cancer 
biology and has led to a greater appreciation of the role 
of the vasculature as drivers of malignancy and drug 
resistance. Targeting tumour angiogenesis is increasingly 
being used in anticancer strategies. These therapies are 
attractive, as endothelial cells from the body are not subject 
to the same selective pressure or genetic instability as 
tumour cells, and may be less likely to develop resistance. 
However, delivery of anti-angiogenic therapy treatment 
must be targeted and based on an understanding of the 
processes that underlie tumour vascular biology.
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DISPARATE FUNCTIONS OF MYELOID-DERIVED 
SUPPRESSOR CELLS IN CANCER METASTASIS
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Abstract
Myeloid-derived suppressor cells comprise a heterogeneous population of immature immune cells that expand during 
the course of cancer progression. These cells adopt an immunosuppressive phenotype that impairs the anti-tumour 
immune response through modulation of T cells, natural killer cells, dendritic cells and macrophages, as evidenced 
both in mouse models of cancer and patients. While much attention has been focused on the immunosuppressive 
roles of myeloid-derived suppressor cells, it is becoming increasingly clear that they can also promote tumour 
progression and metastasis via other immune-independent functions, including the regulation of angiogenesis 
and tumour invasiveness. Their arrival at metastatic sites prior to the arrival of tumour cells also contributes to the 
formation of a favourable pre-metastatic niche. This review will summarise the various roles for myeloid-derived 
suppressor cells, including new evidence that supports a role in promoting a favourable pre-metastatic environment 
for bone metastasis.  
That cancer progression relies heavily on the interaction 
between malignant cells and host stromal cells within 
the tumour microenvironment, including ﬁ broblasts, 
endothelial cells and immune cells, is now well accepted. 
Although initially thought to have anti-tumour roles, it is now 
well known that immune cells can also become inﬂ uenced 
by tumour-derived and other microenvironmental factors 
and adopt a pro-tumorigenic, immunosuppressive 
phenotype. In the last three decades, much attention has 
been focused on the roles of myeloid-derived suppressor 
cells (MDSCs) in this process. Mostly known for their ability 
to suppress the anti-tumour immune response through
